Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

Werner Rainer, CEO of XSpline comments on the first patient enrolling in the International Clinical Trial for the company’s Non-Invasive Cardiac Resynchronization Therapy

Werner Rainer, CEO of XSpline comments on the first patient enrolling in the International Clinical Trial for the company's Non-Invasive Cardiac Resynchronization Therapy

(IN BRIEF) I am excited to share that XSpline SPA and Ordensklinikum Linz Elisabethinen Hospital have enrolled the first patient in the CRT-DRIVE clinical trial. Our cloud-based XSpline Cloud technology offers non-invasive cardiac panoramic mapping to select individual CRT treatment … Read the full press release

Dr. Georgios Kollias, M.D., comments on the enrollment of the first patient in the Clinical Study for Cardiac Resynchronization Therapy Using XSpline Cloud’s Non-Invasive Technology

Dr. Georgios Kollias, M.D. comments on the enrollment of the first patient in the Clinical Study for Cardiac Resynchronization Therapy Using XSpline Cloud's Non-Invasive Technology

(IN BRIEF) Dr. Georgios Kollias, the principal investigator for the clinical trial in Austria, expressed great satisfaction with the XSpline Cloud software, a non-invasive cardiac panoramic mapping technology designed to select individual CRT treatment strategies and predict outcomes. As the … Read the full press release

XSpline SPA / University of Linz (Austria): the first patient has been enrolled in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE)

XSpline Cloud: First-in-class cloud platform for personalized cardiac resynchronization therapy evaluated in International Clinical Trial; first procedure performed at the Ordensklinikum Linz Elisabethinen Hospital (Austria). (IN BRIEF) XSpline SPA, an Italian start-up company, and the Ordensklinikum Linz Elisabethinen Hospital in … Read the full press release

EHRA 2023: Celebrando 20 años de avances en el manejo de la arritmia

(NOTICIA EN BREVE) El congreso científico EHRA 2023 de la European Heart Rhythm Association (EHRA), una rama de la Sociedad Europea de Cardiología (ESC), se llevará a cabo del 16 al 18 de abril en Barcelona, España, así como en … Read the full press release

EHRA 2023: Celebrating 20 Years of Advancements in Arrhythmia Management

(IN BRIEF) The EHRA 2023 scientific congress of the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), will be held from April 16 to 18 in Barcelona, Spain, as well as online. The congress … Read the full press release

Researchers discover new approach to treating brain hemorrhage with protein therapy

(IN BRIEF) Researchers from the Brain Repair laboratory at the University of Helsinki have investigated whether a protein called cerebral dopamine neurotrophic factor (CDNF) has potential as a treatment for intracerebral haemorrhage, a condition where bleeding into brain tissue causes … Read the full press release

Sanofi’s Acquisition of Provention Bio Expands Immune-Mediated Disease Portfolio

(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, for $2.9 billion. The acquisition includes Provention Bio’s first-in-class therapy for type 1 diabetes, TZIELD, which was approved in the … Read the full press release

Merck and Intel fund academic research program in Europe to drive sustainable semiconductor manufacturing with AI and machine learning

(IN BRIEF) Merck and Intel have signed a memorandum of understanding to invest in a new academic research program aimed at driving innovation in semiconductor manufacturing processes and technologies using artificial intelligence (AI) and machine learning. The companies will jointly … Read the full press release

Sandoz to Invest Over $400 Million in New Biologics Plant in Slovenia

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia, in a move expected to be worth at least USD 400 million. The … Read the full press release

AstraZeneca cherche la prochaine vague d’innovation thérapeutique avec le défi postdoctoral R&D 2023

(ACTUALITÉ EN BREF) AstraZeneca a lancé le Défi postdoctoral R&D 2023, qui invite les étudiants en dernière année de médecine et/ou de doctorat et les chercheurs postdoctoraux du monde entier à soumettre leurs propres propositions de recherche. L’initiative est conçue … Read the full press release

AstraZeneca seeks next wave of therapeutic innovation with 2023 R&D Postdoctoral Challenge

(IN BRIEF) AstraZeneca has launched the 2023 R&D Postdoctoral Challenge, which invites final-year MD and/or PhD students and postdoctoral researchers from around the world to submit their own research proposals. The initiative is designed to promote diversity of thought and … Read the full press release

QIAGEN and Servier Collaborate to Develop Diagnostic Test for Hard-to-Treat Blood Cancer

(IN BRIEF) QIAGEN has entered into a partnership with global pharmaceutical group, Servier, to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat acute myeloid leukemia (AML). QIAGEN will develop and validate a real-time … Read the full press release

Die Global Antibiotic Research and Development Partnership und die University of Liverpool bündeln ihre Kräfte, um Antibiotikaresistenzen zu bekämpfen

(IN KÜRZE) Die University of Liverpool und die Global Antibiotic Research and Development Partnership (GARDP) haben eine Absichtserklärung unterzeichnet, um bei neuen Projekten zur Bekämpfung der Antibiotikaresistenz (AMR) zusammenzuarbeiten. Sie arbeiten seit 2018 zusammen, um neue Behandlungsmöglichkeiten für Neugeborene mit … Read the full press release

Global Antibiotic Research and Development Partnership and University of Liverpool join forces to fight antimicrobial resistance

(IN BRIEF) The University of Liverpool and the Global Antibiotic Research and Development Partnership (GARDP) have signed a Memorandum of Understanding to collaborate on new projects to address antimicrobial resistance (AMR). They have been working together since 2018 to advance … Read the full press release

Evonik expands lipid manufacturing capabilities for advanced drug delivery

(IN BRIEF) Specialty chemicals company Evonik has opened a lipid launch facility at its site in Hanau, Germany. The good manufacturing practice facility, which opened on 8 March 2023, will enable Evonik to provide customers with quantities of lipids as … Read the full press release

Novo Nordisk renforce son équipe de direction avec de nouvelles nominations

(ACTUALITÉ EN BREF) Novo Nordisk a annoncé des changements dans son équipe de direction. Monique Carter, l’actuelle vice-présidente exécutive de Global People & Organisation, quitte l’entreprise pour poursuivre une opportunité externe et sera remplacé par Tania Sabroe, qui a été … Read the full press release

Novo Nordisk strengthens executive team with new appointments

(IN BRIEF) Novo Nordisk has announced changes to its executive management team. Monique Carter, the current EVP of Global People & Organisation, is leaving the company to pursue an external opportunity and will be succeeded by Tania Sabroe, who has … Read the full press release

El CEO de Firmenich, Gilbert Ghostine, encabezará a Sandoz como presidente designado de la nueva junta directiva

(NOTICIA EN BREVE) Gilbert Ghostine ha sido designado presidente designado de la nueva junta directiva de Sandoz, tras el anuncio de la junta directiva de Novartis. La nueva Junta Directiva de Sandoz se formará en la segunda mitad de 2023, … Read the full press release

Firmenich CEO Gilbert Ghostine to Lead Sandoz as Chairman-Designate of New Board of Directors

(IN BRIEF) Gilbert Ghostine has been appointed as Chairman-designate of the new Board of Directors of Sandoz, following the announcement by Novartis Board of Directors. The new Board of Directors of Sandoz will be formed in the second half of … Read the full press release

Nuovi progressi nel trattamento del cancro alla prostata: Darolutamide sta per essere approvato nell’UE

Non destinato ai media statunitensi e britannici (NOTIZIA IN BREVE) Il comitato per i medicinali per uso umano dell’Agenzia europea per i medicinali ha raccomandato l’autorizzazione all’immissione in commercio nell’Unione europea di darolutamide, un inibitore orale del recettore degli androgeni, … Read the full press release